Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 11-12, 2006, Pages 1563-1573

  Gatselis, N K ^a   Georgiadou, S P ^a   Koukoulis, G K ^a   Tassopoulos, N ^b   Zachou, K ^a   Liaskos, C ^a   Hatzakis, A ^c   Dalekos, G N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b West Attica Hospital   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; PARIETAL CELL ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SMOOTH MUSCLE ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOIMMUNITY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 33845512744     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03165.x     Document Type: Article

References (50)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31 (Suppl. 1): 39-42.
3. Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999; 30: 366-75.
4. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339: 321-3.
5. Kambhu S, Falldorf P, Lee JS. Endogenous retroviral long terminal repeats within the HLA-DQ locus. Proc Natl Acad Sci U S A 1990; 87: 4927-31.
6. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31 (Suppl. 1): 210-6.
7. Mason AL, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351: 1620-4.
8. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44: 525-8.
9. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-8.
10. Yamano S, Renard JN, Mizuno F, et al. Retrovirus in salivary glands from patients with Sjogren's syndrome. J Clin Pathol 1997; 50: 223-30.
11. Tsianos EV, Dalekos GN, Merkouropoulos MH, Tsatsoulis A, Seferiadis KI. Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. Eur J Gastroenterol Hepatol 1994; 6: 547-51.
12. Bortolotti F, Vajro P, Balli F, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614-20.
13. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000; 79: 47-56.
14. Dalekos GN, Makri E, Loges S, et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 2002; 14: 35-42.
15. Dalekos GN, Manoussakis MN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. Eur J Clin Invest 1993; 23: 219-25.
16. Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001; 3: 277-85.
17. Fabbri C, Jaboli MF, Giovanelli S, et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003; 9: 1487-90.
18. Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 112: 471-6.
19. Muratori P, Muratori L, Stroffolini T, et al. Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol 2003; 131: 118-21.
20. Squadrito G, Previti M, Lenzi M, et al. High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy. Dig Dis Sci 2003; 48: 349-53.
21. Wu YY, Hsu TC, Chen TY, et al. Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol 2002; 128: 347-52.
22. Monti V, Aghemo A, Rumi MG, et al. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies. Antivir Ther 2005; 10: 715-20.
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 47: 975-82.
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
25. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
26. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-9.
27. Dalekos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tsianos EV. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10: 933-9.
28. Dalekos GN, Kistis KG, Boumba DS, et al. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol 2000; 12: 67-74.
29. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47.
30. Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45: 435-41.
31. Noda K, Enomoto N, Arai K, et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996; 31: 716-22.
32. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-6.
33. Wada M, Kang KB, Kinugasa A, et al. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997; 36: 248-54.
34. Wasmuth HE, Stolte C, Geier A, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4: 4.
35. Muratori P, Muratori L, Guidi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501-7.
36. Gatselis NK, Georgiadou SP, Tassopoulos N, et al. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. World J Gastroenterol 2005; 11: 482-7.
37. Satra M, Dalekos GN, Kollia P, Vamvakopoulos N, Tsezou A. Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections. J Viral Hepat 2005; 12: 488-93.
38. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
39. Simmonds P, McOmish F, Yap PL, et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993; 74: 661-8.
40. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
41. Koukoulis GK. Chronic hepatitis C: grading, staging, and searching for reliable predictors of outcome. Hum Pathol 2001; 32: 899-903.
42. Zachou K, Liaskos C, Christodoulou DK, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003; 33: 161-8.
43. Georgiadou SP, Zachou K, Rigopoulou E, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004; 11: 358-65.
44. Dalekos GN, Obermayer-Straub P, Bartels M, et al. Cytochrome P450 2A6: new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol 2003; 39: 800-6.
45. Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. Gut 1993; 34: 658-64.
46. Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB, Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37: 1320-6.
47. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-8.
48. Gregorio GV, Jones H, Choudhuri K, et al. Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alfa. Hepatology 1996; 24: 520-3.
49. Stroffolini T, Colloredo G, Gaeta GB, et al. Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat 2004; 11: 257-62.
50. Gregorio GV, Choudhuri K, Ma Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003; 133: 404-13.